Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 62, Issue 3, 1997, Pages 285-287

  Koudriavtseva, T ^a,d   Thompson, A J ^b   Fiorelli, M ^a   Gasperini, C ^a   Bastianello, S ^a   Bozzao, A ^a   Paolillo, A ^a   Pisani, A ^a   Galgani, S ^c   Pozzilli, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Enhanced MRI; Predictivity; Relapsing remitting multiple sclerosis

Indexed keywords

GADOLINIUM PENTETATE; RECOMBINANT BETA INTERFERON;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE;

EID: 0030935805     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.62.3.285     Document Type: Article

References (14)

1. Miller DH, Ormerod IEC, McDonald WI, et al. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry 1988;51:1569-71.
2. Miller DH, Ormerod IEC, Rudge P, et al. The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord. Ann Neurol 1989;26: 635-9.
3. Lee LH, Hashimoto SA, Hooge JP, et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-years follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1991;41:657-60.
4. Beck RW, Cleary PA, Tobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329: 1764-9.
5. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Brain 1993;116:135-46.
6. Filippi M, Horsfield MA Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-41.
7. Smith ME, Stone LA, Albert PS, et l. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neuro 1993;33:480-9.
8. Losseff NA, Kingsley DPE, McDonald WI, et al. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996;1:218-22.
9. Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-1.
10. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61:251-8.
11. Wicks D, Tofts PS, Miller DH et al. Volume measurements of multiple sclerosis with magnetic resonance imaging. Neuroradiology 1992;34:475-9.
12. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol 1994; 36:S108-12.
13. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-94.
14. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37:611-9.